Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10512612 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
US10512613 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
US10292939 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
US10449159 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
US10111839 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
US10688060 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
US10507186 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
US9974752 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
US10292938 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
US10568841 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
US10500162 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
US10722473 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Nov, 2038
(15 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M (M) | Jun 28, 2024 |
Market Authorisation Date: 27 February, 2019
Treatment: Method of treating attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
16
United States
7
Canada
3
Australia
2
Singapore
2
Japan
2
Chile
1
Mexico
1
Argentina
1
Brazil
1
China
1
South Africa
1
EA
1
Israel
1
Taiwan
1
Korea, Republic of
1
Hong Kong
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10905652 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
US9028868 | IRONSHORE PHARMS | Methods and compositions for treatment of attention deficit disorder |
Mar, 2032
(8 years from now) | |
US9034902 | IRONSHORE PHARMS | Methods for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
US8916588 | IRONSHORE PHARMS | Methods for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
US9603809 | IRONSHORE PHARMS | Methods of treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
US10292937 | IRONSHORE PHARMS | Methods of treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
US10617651 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
US10881618 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
US11241391 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
US11241392 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
US9498447 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
US9283214 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
US9023389 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
US8927010 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) | |
US10182995 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(8 years from now) |
Market Authorisation Date: 08 August, 2018
Treatment: Method of treating attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
28
United States
6
Japan
3
Australia
3
European Union
2
Singapore
2
China
2
Denmark
2
Portugal
2
Spain
2
Korea, Republic of
1
Canada
1
Mexico
1
Brazil
1
South Africa
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7691880 | SPECGX LLC | Methylphenidate solution and associated methods of administration and production |
Oct, 2024
(1 year, 4 months from now) |
Market Authorisation Date: 19 December, 2002
Treatment: NA
Dosage: SOLUTION;ORAL
3
United States
1
Canada
1
Mexico
1
China
1
Australia
1
Spain
1
Japan
1
Austria
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8202537 | NEXTWAVE PHARMS | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(3 years from now) | |
US8287903 | NEXTWAVE PHARMS | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(7 years from now) | |
US8999386 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(10 years from now) | |
US11633389 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(10 years from now) | |
US9545399 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(10 years from now) | |
US9295642 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(10 years from now) | |
US9844544 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(10 years from now) | |
US11103495 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(10 years from now) | |
US10857143 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(10 years from now) | |
US11103494 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(10 years from now) |
Market Authorisation Date: 04 December, 2015
Treatment: A method of providing a subject with therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet accor...
Dosage: TABLET, EXTENDED RELEASE, CHEWABLE;ORAL
53
United States
4
Australia
4
Denmark
4
Spain
4
European Union
3
Canada
3
Brazil
3
Israel
2
China
1
Russia
1
Japan
1
Taiwan
1
Austria
1
Korea, Republic of
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8062667 | NEXTWAVE | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2029
(5 years from now) | |
US9040083 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(7 years from now) | |
US8563033 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(7 years from now) | |
US8956649 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(7 years from now) | |
US8465765 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(7 years from now) | |
US8778390 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(7 years from now) | |
US8287903 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(7 years from now) |
Market Authorisation Date: 27 September, 2012
Treatment: Treating a patient having a condition susceptible to treatment with methylphenidate, such as adhd, by administering the formulation recited in claims 1 or 2; Method of treating attention deficit hyper...
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
35
United States
3
Australia
3
Denmark
3
Spain
3
European Union
2
Canada
2
Brazil
2
China
2
Israel
1
Russia
1
Japan
1
Taiwan
1
Austria
1
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic